The Increased Expression of Integrin α6 (ITGA6) Enhances Drug Resistance in EVI1high Leukemia by Yamakawa, Norio et al.
The Increased Expression of Integrin a6 (ITGA6)
Enhances Drug Resistance in EVI1
high Leukemia
Norio Yamakawa
., Kazuko Kaneda
., Yusuke Saito, Emi Ichihara, Kazuhiro Morishita*
Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
Abstract
Ecotropic viral integration site-1 (EVI1) is one of the candidate oncogenes for human acute myeloid leukemia (AML) with
chromosomal alterations at 3q26. High EVI1 expression (EVI1
high) is a risk factor for AML with poor outcome. Using DNA
microarray analysis, we previously identified that integrin a6 (ITGA6) was upregulated over 10-fold in EVI1
high leukemia cells.
In this study, we determined whether the increased expression of ITGA6 is associated with drug-resistance and increased
cell adhesion, resulting in poor prognosis. To this end, we first confirmed the expression pattern of a series of integrin genes
using semi-quantitative PCR and fluorescence-activated cell sorter (FACS) analysis and determined the cell adhesion ability
in EVI1
high leukemia cells. We found that the adhesion ability of EVI1
high leukemia cells to laminin increased with the
increased expression of ITGA6 and integrin b4 (ITGB4). The introduction of small-hairpin RNA against EVI1 (shEVI1) into
EVI1
high leukemia cells reduced the cell adhesion ability and downregulated the expression of ITGA6 and ITGB4. In addition,
the overexpression of EVI1 in EVI1
low leukemia cells enhanced their cell adhesion ability and increased the expression of
ITGA6 and ITGB4. In a subsequent experiment, the introduction of shRNA against ITGA6 or ITGB4 into EVI1
high AML cells
downregulated their cell adhesion ability; however, the EVI1
high AML cells transfected with shRNA against ITGA6 could not
be maintained in culture. Moreover, treating EVI1
high leukemia cells with neutralizing antibodies against ITGA6 or ITGB4
resulted in an enhanced responsiveness to anti-cancer drugs and a reduction of their cell adhesion ability. The expression of
ITGA6 is significantly elevated in cells from relapsed and EVI1
high AML cases; therefore, ITGA6 might represent an important
therapeutic target for both refractory and EVI1
high AML.
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Introduction
Ecotropic viral integration site-1 (EVI1) is an oncogenic
transcription factor for murine and human myeloid leukemia
[1,2]. Human EVI1 is localized on chromosome 3q26 [3].
Although only approximately 1 to 3% of acute myeloid leukemia
(AML) cases result from a translocation in 3q26, the elevated
expression of EVI1 has been detected in 5% to 10% of AML
cases in the absence of chromosomal abnormalities at 3q26 [4].
AML with EVI1 high expression (EVI1
high) is a poor prognosis
subtype of AML that does not respond to currently available
treatments [5].
EVI1 is a nuclear transcription factor with a DNA-binding zinc
finger, an acidic amino acid cluster region and C-terminal binding
protein (CtBP) motifs [6,7]. Although EVI1 has been reported to
transcriptionally repress or suppress TGFb signaling by recruiting
Smad3 and the co-repressor CtBP [8–10], we showed that EVI1 is
directly associated with the GATA-2 promoter and upregulates
GATA-2 transcription to maintain hematopoietic stem cells
(HSCs) and AML with EVI1
high expression [11,12] in EVI1-
deficient mice. In addition to the observed reduction in GATA-2
expression, other important factors for HSC maintenance,
including Angiopoietin-1 and Tie-2, were also de-regulated in
EVI1-deficient mice [11]. These results suggest that murine Evi1
might de-regulate transcription factors or other signal transduction
molecules necessary for HSC maintenance [11]. However, we do
not know precisely how Evi1 is involved in the maintenance of
HSCs.
Recently, there has been increased interest in understanding the
regulatory interactions between osteoblasts and HSCs in the bone
marrow microenvironment. Individual HSCs are typically an-
chored to the stroma via a network of adhesion molecules [13,14].
Recent studies have indicated the importance of these adhesion
molecules (integrins and cadherins) in hematopoietic stem cell
development and have shown that they function as key elements
for the detection and translation of the extrinsic cues provided by
the hematopoietic microenvironmental niche [15,16]. The
integrins are heterodimeric complexes composed of two noncova-
lently associated transmembrane glycoprotein subunits: one from
sixteen different alpha (a) subunits and the other from eight
different beta (b) subunits [17,18]. abVery late antigen 4 (VLA4), a
a4/b1 integrin heterodimer, participates in both cell-cell and cell-
matrix interactions with vascular cell adhesion molecule-1
(VCAM1) and fibronectin (FN). In adult mice, VLA4/VCAM1
interactions are key elements in the mobilization and homing of
hematopoietic stem cells to bone marrow [19]. Moreover,
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poietic progenitor cells from the bone marrow to the peripheral
blood [20]. Studies addressing the role of VLA4 in AML cell lines
have described the drug resistance induced by the interaction of
tumor cells with stromal cells or the extracellular matrix (ECM) as
cell adhesion-mediated drug resistance (CAM-DR) [21,22]. In an
analysis of 175 adult AML patients, however, VLA4 expression
was not significantly associated with the response to anti-cancer
drugs or with relapse-free or overall survival rates [23]. Thus,
other adhesion molecules may also be important in the
maintenance of HSC and leukemia stem cells.
In this study, we observed that the cell adhesion ability of the
EVI1
high AML cells was higher than that of the EVI1
low cells. The
increased adhesion of EVI1
high AML cells was dependent on the
expression of the integrins a6 (ITGA6) and b4 (ITGB4) in
complex with laminin, particularly laminin-332. Because the
increased adhesion ability of the AML cells increased their
resistance to chemotherapy, and the expression of ITGA6 was
significantly higher in AML cases in relapse, ITGA6 might be a
novel molecular target in EVI1
high leukemia cells.
Results
Overexpression of ITGA6 enhances the ability of EVI1
high
leukemia cell lines to adhere to matrigel and laminin
To search for novel molecular targets in refractory myeloid
leukemia with high EVI1 expression, we previously analyzed the
gene expression profiles of 12 human myeloid cell lines using an
oligonucleotide microarray (Human Genome U133 Plus 2.0
Array; Affymetrix) containing 38,500 genes [24]. We identified
ITGA6 in 26 selected genes that were upregulated over ten-fold in
EVI1
high leukemia cells (p,0.01). To confirm the results of the
microarray analysis, the expression levels of a series of integrin
genes were determined in three EVI1
low and EVI1
high cell lines
using semi-quantitative RT-PCR. We determined the levels of the
eight different b integrin genes (1 through 8), fifteen different a
integrin genes (1 through 10, E, L, M, V, and X) and two cadherin
molecules (N and VE). As shown in Fig. S1A, ITGB1, ITGB3,
ITGA4, and ITGA5 were expressed in five of the six leukemia cell
lines, and ITGB4 and ITGA6 were specifically expressed in the
three EVI1
high leukemia cell lines. To confirm the results of the
expression patterns of the integrin genes, we used the six cell lines
and two primary leukemia cell lines from patients with the inv(3)
(q21q26) subtype (PT9 and PT11) [24] to determine the
expression of ITGB1, ITGB4, ITGA4, and ITGA6. ITGB1 and
ITGA4 were expressed as very late antigen-4 (VLA-4) in most of
the cell lines, but ITGB4 and ITGA6 were expressed in all three
leukemia cell lines and in the two primary EVI1
high leukemia cell
lines (Fig. 1A).
Because a number of integrin genes are involved in binding to
fibronectin, laminin and matrigel [15,16], we compared the cell
adhesion ability of EVI1
high and EVI1
low leukemia cell lines. The
three human EVI1
low myeloid cell lines (HL60, U937, and K562)
showed a reduced binding affinity to laminin and matrigel but an
increased binding affinity to fibronectin. In contrast, the three
EVI1
high cell lines (UCSD/AML1, MOLM1, and HNT34)
exhibited an increased affinity for laminin, matrigel and
fibronectin, with significant differences (Fig. 1B). Because the
primary component of the matrigel used in this experiment is the
laminin complex, the enhanced cell adhesion ability of EVI1
high
leukemia cells might depend on binding to the laminin complex.
We also investigated the ability of various leukemia cells to
adhere to the murine bone marrow stromal/osteoblastic cell line
MC3T3-E1. As shown in Fig. 1D, a higher percentage of cells in
the three EVI1
high leukemia cell lines (UCSD/AML1, MOLM1
and HNT34) were attached to the MC3T3-E1 cells compared
with the three EVI1
low leukemia cell lines (HL60, K562 and
U937), and this difference was statistically significant (p,0.01).
Because the EVI1
high leukemia cell lines exhibited an enhanced
ability to adhere to the laminin complex (Fig. 1C), we propose
that the laminin complex might be one of the main molecular
targets of this increased adhesion to the MC3T3-E1 cells.
The expression of ITGA6 and ITGB4 is dependent on the
expression of EVI1
To determine which of the integrin genes were dependent on
EVI1 expression, small hairpin RNA against EVI1 (shEVI1) were
introduced into UCSD/AML1 cells with EVI1
high. Three UCSD/
AML1 cell lines expressing shEVI1 (AML1/shEVI1-1 to -3), and a
control cell line expressing an shRNA for firefly luciferase (shLuc)
(AML1/shLuc) were established. Because the EVI1 expression was
significantly downregulated in the AML1/shEVI1-1 to 3 cell lines
(Fig. 2A), we determined the expression of a series of integrin
genes using semi-quantitative RT-PCR (Fig. S1B and Fig. 2A).
The results showed that the expression of ITGB3, ITGB4,
ITGA6, ITGA9, and VE-cadherin was downregulated along with
EVI1 in the AML1/shEVI1-1 to 3 cell lines. The high expression
of ITGB3, ITGB4 and ITGA6 in the UCSD/AML1 cells and the
downregulation of ITGA6, ITGB4 and ITGB3 in the AML1/
shEVI1-1 cells were confirmed through immunofluorescence
staining and FACS analysis (Fig. 2B). Moreover, ITGB4, ITGA6,
ITGA9, and VE-cadherin were also downregulated in the HNT34
cell line, and PT9 and PT11 primary AML cell lines upon shEVI1
transfection, which was associated with a reduction in matrigel cell
adhesion (Figs. S1C to F). Taken together, the results
demonstrated that ITGB4, ITGA6, ITGA9, and VE-cadherin
are the candidate integrin genes with increased adhesion ability in
EVI1
high leukemia cells. Moreover, we determined the cell
adhesion ability of the AML1/shEVI1 cell lines and found that
the adhesion of AML1/shEVI1-1 to 3 cells to matrigel was
significantly reduced compared with that of the parental UCSD/
AML1 and AML1/shLuc cells (Fig. 2C). The cell adhesion of the
AML1/shEVI1-1 cells to laminin, but not to fibronectin, was also
significantly reduced compared with that of the AML1/shLuc cells
(Fig. 2D and E).
In a subsequent experiment, we transiently introduced EVI1
and GFP expression vectors into the EVI1
low U937 cells and
determined the resulting levels of expression of the various integrin
genes. The adhesion of U937/EVI1 cells to matrigel was increased
three-fold, and the expression of ITGB3, ITGB4 and ITGA6 was
also increased in U937/EVI1 cells relative to their adhesion ability
and expression in the U937/parental and U937/GFP cells
(Fig. 2F and Fig. S1G). Because ITGB4 and ITGA6 form a
heterodimer that binds to the laminin receptor and treatment with
a neutralizing antibody to ITGB3 did not suppress the cell
adhesion ability of EVI1
high leukemia cells (Fig. 3G), we further
characterized the relationship between the expression of ITGA6/
ITGB4 and the increased adhesion ability of the EVI1
high
leukemia cells.
The adhesion ability of leukemia cells with EVI1
high
expression is specifically dependent on the expression of
ITGA6 and ITGB4
To evaluate whether the adhesion ability of the EVI1
high
leukemia cells was specifically dependent on the expression of
ITGA6 or ITGB4, shRNA against ITGA6 or ITGB4 was
introduced into UCSD/AML1 cells using an Amaxa Nucleofector,
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expression of ITGA6 and the cell adhesion ability were significantly
reduced in UCSD/AML1 cells transfected with shITGA6 (AML1/
shITGA6) (Fig. 3A and D). Similar results were obtained in
UCSD/AML1 cells transfected with shITGB4 (AML1/shITGB4)
(Fig. 3B andE). The growth rate of the AML1/shITGA6 cells was
Figure 1. Higher cell adhesion ability in AML cell lines with EVI1
high expression. A. The expression of four integrin genes (ITGB1, ITGB4,
ITGA4 and ITGA6), EVI1 and b-actin as a control was determined by semiquantitative RT-PCR in three different EVI1
low and EVI1
high AML cell lines and
two primary AML cells lines with high EVI1 expression (PT9 and PT11). B. Six AML cell lines with low or high EVI1expression, as indicated in the figure,
were incubated in culture medium on BSA, collagen, fibronectin, laminin or matrigel-coated plates; the percentage of the total number of incubated
cells that adhered to the plates was designated as the binding activity (%). Each experiment was performed in triplicate, and the experiments were
independently repeated at least three times. The data are given the as the mean 6 standard error (S.E). The statistical analysis was performed using
the Student’s t-test (*p,0.05, vs. BSA-coated plate). C. Six AML cell lines were incubated with the murine osteoblastic cell line MC3T3-E1, and the
percentage of cells that bound to MC3T3-E1 cells was determined. Each experiment was performed in triplicate, and the experiments were
independently repeated at least three times. The statistical analysis was performed using the Student’s t-test (*p,0.05, vs. EVI1
low cell lines).
doi:10.1371/journal.pone.0030706.g001
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the AML1/shITGB4 grew at rate similar to the parental UCSD/
AML1 control cells, suggesting that the signal transduction of
ITGA6 is essential for the maintenance of leukemia cells. Because
ITGA6 forms a heterodimer with ITGB4 or ITGB1, shITGB1 was
introduced into UCSD/AML1 cells, and their adhesion to matrigel
was measured. The adhesion of UCSD/AML1 cells to matrigel did
not change significantly upon transfection with shITGB1 (Fig. 3C
and F). These results suggest that the ITGA6 and ITGB4
heterocomplex is the primary cell adhesion molecule on EVI1
high
leukemia cells.
To confirm the ITGA6 dependence of the increased cell
adhesion of EVI1
high leukemia cells, we used a series of
neutralizing antibodies. Two leukemia (UCSD/AML1 and
MOLM1) and two primary human AML (PT9 and PT11) cells
lines were cultured on matrigel and treated with or without anti-
ITGA6, ITGB2, ITGB3, or ITGB4 antibodies. Two days after
treatment, the binding activity of all four cell lines was significantly
reduced by the treatment with anti-ITGA6 or anti-ITGB4
antibodies; however, isotype IgG, anti-ITGB2 or anti-ITGB3
antibodies did not inhibit the binding of EVI1
high leukemia cells to
matrigel (Fig. 3G).
Because the EVI1
high leukemia cells exhibited an increased
adherence to the murine osteoblastic cell line MC3T3-E1 (Fig. 1D)
we examined whether this adhesion was dependent on ITGA6 or
ITGB4 expression by treating with a neutralizing antibody. Two
EVI1
low (K562 and U937) and three EVI1
high (UCSD/AML1, PT9
and PT11) leukemia cell lines wereco-cultured with MC3T3-E1 cells,
and the mixed cultures were subsequently treated with anti-ITGA6
or anti-ITGB4 antibody or the control isotype anti-rabbit IgG. The
ability of the three EVI1
highleukemiacellstobindtoMC3T3-E1cells
was significantly reduced upon treatment with anti-ITGA6 or anti-
ITGB4 antibody, whereas the binding ability of the two EVI1
low
leukemia cells did not change (Fig. 3H). To confirm this result, we
examined the adhesion of U937/parental and U937/EVI1 cells to
matrigel upon treatment with anti-ITGA6 antibody. The anti-
ITGA6 antibody significantly inhibited the cellular adhesion of
U937/EVI1 cells to matrigel, but did not inhibit the cell adhesion of
the parentalU937 cells(Fig. 3I).Therefore,theexpressionofITGA6
and ITGB4 was EVI1 dependent, and the increased expression of
ITGA6 and ITGB4 in EVI1
high leukemia cells increased their ability
to adhere to the osteoblastic MC3T3-E1 cell line.
The downregulation of laminin-332 in osteoblastic
MC3T3-E1 cells partially inhibits binding to EVI1
high
leukemia cells
The ITGA6/IGTB4 heterocomplex has a clear specificity for
laminin-332 (a3b3g2) or laminin-511 (a5b1g1) [25]. Therefore, we
measured the expression of a series of laminin a, b, and g chains in
MC3T3-E1 cells; the expression of each laminin chain was clearly
detected in these cells (Fig. S2). We subsequently introduced
shRNA against the a3 chain of laminin-332 (shLN332) into
MC3T3-E1 cells and measured the ability of the MC3T3-E1 cells
to adhere to various types of myeloid leukemia cells. After the
introduction of shLN332 or shLuc into MC3T3-E1 cells (MC3T3-
E1/shLN332 or MC3T3-E1/shLuc, respectively), the expression
of the a3 chain of laminin-332 was significantly reduced (Fig. 4A),
but the expression of the g3 chain of laminin-332 and b-actin were
not changed. Compared to the MC3T3-E1/shLuc cells, the
MC3T3-E1/shLN332 cells displayed significantly reduced adhe-
sion to the EVI1
high cell lines UCSD/AML1, MOLM1 and
HNT34. However, their adhesion to the leukemia cell lines with
EVI1
low expression, such as HL60, K562, and U937, did not
change (Fig. 4B). Moreover, the UCSD/AML1/shEVI1 cells
displayed reduced adhesion to the MC3T3-E1/shLuc cells
compared with that of the UCSD/AML1 cells, whereas the
adhesion of the UCSD/AML1/shEVI1 cells to the MC3T3-E1/
shLuc and MC3T3-E1/shLN332 cells did not change. These data
suggest that the increased adhesion of the leukemia cell lines with
EVI1
high expression is mainly dependent on the laminin complex,
particularly laminin-332.
EVI1
high leukemia cells treated with ITGA6 or ITGB4-
neutralizing antibodies or small hairpin RNA against EVI1
or ITGB4 recover drug sensitivity
We next determined whether treating EVI1
high leukemia cells
with a neutralizing antibody against integrin improves the drug
sensitivity of the cells in the adhered state. Two EVI1
high leukemia
cell lines, UCSC/AML1 and MOLM1, and two primary leukemia
cell lines, PT9 and PT11, were used in this experiment; the IC50
of Ara-C for these cells cultured on the matrigel coated plates was
approximately 10
26 M( Fig. S3). The four cell lines were seeded
on matrigel-coated culture plates ith or without anti-ITGA6 or
anti-ITGB4 antibodies in the presence of 10
26 M Ara-C. After
four days of culture, the percentage of surviving cells in the
cultures treated with anti-ITGA6 or anti-ITGB4 antibodies were
significantly reduced in the two EVI1 and primary AML cell lines
compared with the control cells (Figs. 5A to D). Because similar
results were also obtained using the anti-cancer drug, VP-16 (Fig.
S4), the treatment with anti-ITGA6 or anti-ITGB4 antibodies or
anti-cancer drugs might recover the drug-sensitivity of EVI1
high
leukemia cells.
To determine whether the effect of Ara-C was dependent on the
cell adhesion ability, AML1/shITGB4, AML1/shEVI1 and
control AML1/shLuc cells were cultured on matrigel-coated or
control BSA-coated plates and treated with Ara-C for three days;
we could not use AML1/shITGA6 cells in this experiment. After
three days of culture, the number of viable AML1/shLuc cells was
Figure 2. The expression of ITGA6 and ITGB4 is specifically dependent on the expression of EVI1. A. The pattern of expression of EVI1
and five integrin genes (ITGB3, ITGB4, ITGA6, ITGA9 and VE-cadherin) in various UCSD/AML1 cell lines. Three cell lines with small hairpin RNA (shRNA)
against EVI1 (shEVI1-1, -2 and -3) and the parental and UCSD/AML1 cell lines harboring an expression vector for shRNA against firefly luciferase were
used to determine the levels of expression of five integrin (ITGB3, ITGB4, ITGA6, ITGA9 and VE-cadherin) and control (EVI1 and b-actin) genes using
RT-PCR. B. The expression of ITGA6, ITGB4 and ITGB3 in AML1/shLuc and AML1/shEVI1-1 was determined using FACS analysis after staining the cells
with PE-conjugated antibodies to specific integrins. C. The same cell lines described in (2a) were assessed for their ability to adhere to the matrigel.
The relative binding activity was calculated by comparison to the basal binding activity of the parental UCSD/AML1 cell line. D and E. The binding
activity of AML1/shLuc and AML1/EVI1-1 cells to laminin (D) and fibronectin (E) was compared. Both cell lines were cultured on laminin or fibronectin-
coated plates. F and G. After the EVI1 expression vector was introduced into the U937 cell line, the expression of five integrin genes (ITGB3, ITGB4,
ITGA6, ITGA9, VE-cadherin) and EVI1 was determined using RT-PCR. b-actin was used as a control (F). The cell adhesion ability of the U937/EVI1, U937/
parental and U937/GFP cell lines was determined (G). H. The expression of ITGA6, ITGB4 and ITGB3 in U937/GFP and U937/EVI1 was determined using
FACS analysis after staining the cells with PE-conjugated antibodies to specific integrins. Each experiment shown in Figure 2C, 2D, 2E, and 2G was
performed in triplicate, and the experiments were independently repeated at least three times. The data are given as the mean 6 S.E. The statistical
analysis was performed using the Student’s t-test (**p,0.05, vs. each control).
doi:10.1371/journal.pone.0030706.g002
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coated plates compared with conventional culture; however, the
percentage of surviving AML1/shITGB4 cells was reduced at
each time point.(Fig. 5E). The survival rate of the AML1/shEVI1
cells in both the conventional and matrigel-coated cultures was
reduced compared with those of the AML1/shLuc and AML1/
shITGB4 cells upon Ara-C treatment, whereas there was no
difference in the survival rates of the AML1/shEVI1 cells cultured
under conventional and matrigel-coated methods under Ara-C
treatment. These results suggest that the drug resistance of
EVI1
high leukemia cells is highly dependent on EVI1 expression
and partially dependent on ITGB4 expression.
EVI1
high leukemia cells become more quiescent when
cultured on the matrigel-coated plates compared with
those cultured on the BSA-coated plates
To confirm the advantages of cell adhesion in drug-responsive-
ness, we determined the growth and cell cycle status of AML cells
with EVI1
high/low, which were cultured on matrigel or BSA-coated
plates. As shown in Fig. 6A, the UCSD/AML cells with EVI1
high
expression (AML1/shLuc) on the matrigel-coated plates grew
more faster rapidly on the matrigel-coated plates than that on the
BSA-coated plates, although the growth rate of the AML1/shLuc
cells was faster than that of the AML1/shEVI1 cells. The cell cycle
analysis represented revealed that, relative to AML1/shLuc cells
cultured on the BSA-coated plates, the population of EVI1
high
AML1 cells in G0/G1 and G2/M phase increased on the
matrigel-coated plates, while the S-phase populations were
decreased; however, each cell cycle population of AML1/shEVI1
cells did not change under either culture condition (Fig. 6B and
C). Moreover, the population of AML1/shLuc cells in the G0
phase was significantly increased on the matrigel-coated plates
compared with the same cells on the BSA-coated plates; however,
the population of AML1/shEVI1 cells in the G0 phase was the
same under both culture conditions (Fig. 6D). Because the
population of U937 cells with high EVI1 expression (U937/EVI1)
Figure 4. Laminin-332 on MC3T3-E1 cells is a main target for binding to EVI1
high leukemia cells. A. The expression of laminin a3 and g2
in MC3T3-E1 cells transfected with shRNA for firefly luciferase (shLuc) or laminin a3 (shLN332) was determined using RT-PCR. The expression of b-actin
was used as an internal expression control. B. The binding of various myeloid leukemia cell lines to the two cell lines MC3T3-E1/shLuc or/shLN332 was
determined. Each experiment was performed in triplicate, and the experiments were independently repeated at least three times. The data are given
as the mean 6 S.E. The statistical analysis was performed using the Student’s t-test (**p,0.01; *p,0.05, vs. control).
doi:10.1371/journal.pone.0030706.g004
Figure 3. The adhesion ability of EVI1
high leukemia is specifically dependent on the expression of ITGA6 and ITGB4. A, B, and C.
UCSD/AML1 cells were transiently transfected with expression vectors for shRNA against ITGA6 (shITGA6), ITGB4 (shITGB4), or ITGB1 (shITGB1), and
the expression of ITGA6, ITGB4 and ITGB1 was determined using RT-PCR. UCSD/AML1 cells transfected with shRNA for firefly luciferase (shLuc) were
used as a control, and the expression of b-actin was used as an internal control. D, E, and F. The cell adhesion ability of the cells in A, B, and C was
determined through co-culture with the MC3T3-E1 cell line. The relative binding activity was calculated by comparison to the basal binding activity of
control AML1/shLuc cells. G. The effect of neutralizing antibodies to the integrins on the cell binding activity of EVI1
high leukemia cells. Two leukemia
(UCSD/AML1 and MOLM1) and two primary human AML (PT9 and PT11) cell lines were cultured on matrigel-coated plates in the presence or absence
of anti-ITGA6, ITGB2, ITGB3, or ITGB4 antibodies. The relative binding activity was calculated by comparison to the basal binding activity of each cell
line treated with the control isotype IgG. H. Two EVI1
low (K562 and U937) and three EVI1
high (UCSD/AML1, PT9 and PT11) leukemia cell lines were
treated with anti-ITGA6 or ITGB4 antibodies or with the control IgG, and the binding of each cell line to the matrigel-coated plates was determined. I.
The parental and EVI1-expressing (U937/EVI1) U937 cell lines were treated with anti-ITGA6 or control IgG, and their binding to the MC3T3-E1 cell line
was determined. The relative binding activity was calculated by comparison to the basal binding activity of the parental U937 cells treated with the
control isotype IgG. Each experiment was performed in triplicate, and the experiments were independently repeated at least three times. The data are
given as the mean 6 S.E. The statistical analysis was performed using the Student’s t-test (*p,0.05, vs. each control).
doi:10.1371/journal.pone.0030706.g003
Drug Resistance in EVI1+ AML with Integrin a6
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30706Drug Resistance in EVI1+ AML with Integrin a6
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30706in the G0-phase was increased on the matrigel-coated plates
compared with those on the BSA-coated plates (Fig. S5), the
increased quiescence of adhered EVI1
high AML cells might be one
of the reasons for resistance to anti-cancer drugs.
Discussion
Resistance to treatment with anti-cancer drugs is determined by
a variety of factors, including somatic cell genetic differences in
tumors and the phenotypes of leukemia stem cells (LSC). LSCs can
infiltrate bone marrow niches, leading to enhanced self-renewal
and proliferation, and enforced quiescence; the resistance to
chemotherapeutic agents and adhesion molecules, such as VCAM-
1 and VLA-4, has been described in the localization and retention
of normal HSCs and/or leukemia cells within the bone marrow
niche [19]. In this manuscript, we examined the cell adhesion
ability of EVI1
high leukemia cells because the increased expression
of EVI1 in AML is a well-known prognostic factor for poor
outcome and is associated with drug resistance [4,5]. We found
that the EVI1
high leukemia cells with increased ITGA6 and
ITGB4 expression exhibited stronger adhesion to laminin
complexes than the EVI1
low leukemia cells; although, the EVI1
low
leukemia cells exhibited increased adhesion to fibronectin.
Moreover, the interaction between EVI1
high leukemia and
MC3T3-E1 osteoblastic cells was partially dependent on lami-
nin-332. The downregulation of EVI1 or ITGB4 in UCSD/
AML1 leukemia cells restored chemo-sensitivity. The knockdown
of ITGA6 expression in EVI1
high leukemia cells greatly reduced
their survival in culture; thus, we conclude that the increased cell
adhesion ability of EVI1
high leukemia cells is primarily dependent
on the expression of ITGA6, and that signaling from IGTA6 is
crucial for the survival of EVI1
high leukemia cells.
The expression of the ITGA6/ITGB4 complex could promote
tumor progression and the metastasis of various cancer cells,
including breast, colorectal, and thyroid carcinomas. Moreover,
the laminin receptor for ITGA6 is ubiquitously expressed in
human and mouse hematopoietic stem and progenitor cells [26].
In combination with ITGA4, ITGA6 expression in hematopoietic
stem and progenitor cells is believed to create a homing receptor
for short-term stem cells [27]. ITGA6 functions during the homing
of fetal liver HPCs but not during the homing and engraftment of
multilineage repopulating HSCs in vivo [28]. Therefore, ITGA6
might function as a laminin receptor to sustain HSCs in the bone
marrow niche. We are now developing anti-human ITGA6/
ITGB4 complex antibodies, which is a new therapy for refractory
AML. In preliminary experiments, we demonstrated that the
number of EVI1
high AML cells was significantly decreased in the
bone marrow after the intravenous injection of anti-human
ITGA6/ITGB4 complex antibodies into NOG immune deficient
mice (data not shown). As a corollary, the increased expression of
the ITGA6/ITGB4 complex in EVI1
high leukemia might be an
important factor in maintaining leukemia stem cells in the bone
marrow.
The adhesion of EVI1
high AML cells became more resistance
to anti-cancer drug therapy, and the population of cells in the
G0-phase was increased. Because the increased population of G0-
phase cells is likely dependent on the expression of EVI1, future
research should focus on the characterization of the mechanism
underlying the increased quiescent of cells through EVI1
expression subsequent to their adhesion to matrigel. Moreover,
the induction of PI-3K/AKT/Bcl-2 signaling through the VLA-4-
fibronectin interaction results in resistance to anoikis and drug-
induced apoptosis [21]; we also showed the cell adhesion of
EVI1
high AML cells to matrigel induced expression of BCL and
phosphorylation of AKT (data not shown). Therefore, the
adhesion of AML cells may provide advantages to the surviving
cells, and the mechanism of drug-resistance is potentially much
more complicated; however, we should characterize the survival
mechanism of leukemia cells in the bone marrow niche.
To support our data, we examined the expression patterns of
ITGA6/ITGB4 and VLA-4 (ITGA4/ITGB1) heterodimers by
comparing the gene expression profiles of EVI1
high and EVI1
low
AML deposited in Gene Expression Omnibus (GSE6891, GEO in
NCBI website) [29]. As shown in Fig. S6, the expression of
ITGA6 was significantly higher in the 12 cases of EVI1
high AML
than in the 10 cases of EVI1
low AML (p,0.05); however, the
differences in expression of ITGB4, ITGA4 and ITGB1 did not
account for the differences between the two groups. We also
determined the expression patterns of four integrin genes from the
expression profiles of AML cases in remission and relapse that
were deposited in GEO at NCBI (GDS1059) [30]. Based on the
expression profiles, the expression of ITGA6 was significantly
higher in the 28 cases of AML with relapse than in the 25 cases
with remission (p,0.05); however, the differences in expression of
ITGB4, ITGA4 and ITGB1 did not account for the difference
between the two groups. These results show that the increased
expression of ITGA6 is an important marker in both EVI1
high and
relapsed AML, which suggests that ITGA6 might be an important
target for the molecular-targeted treatment of refractory leukemia,
including EVI1
high AML.
Materials and Methods
Cell lines and culture conditions
The MOLM1, HNT34, U937, K562, and HL60 cells were
cultured in RPMI1640 medium supplemented with 10% fetal calf
serum at 37uC and 5% CO2. The UCSD/AML1, PT9 and PT11
cells [24] were cultured in RPMI1640 medium supplemented with
10% fetal calf serum and human granulocyte-macrophage colony
stimulating factor (GM-CSF, 1 ng/ml) at 37uC and 5% CO2. The
MOLM1 cells were purchased from the Hayashibara Institute,
and the MC3T3-E1 and HNT34 cells were purchased from the
RIKEN cell bank. The 293T cells were cultured in high-glucose
DMEM supplemented with 10% fetal calf serum, and the
MC3T3-E1 cells were cultured in MEM alpha supplemented
with 10% fetal calf serum.
Oligonucleotide microarray
This experimental method was previously described [24].
Figure 5. Drug sensitivity of EVI1
high leukemia cells is restored by treatment with neutralizing antibodies to ITGA6 or ITGB4 or by
transfection with small hairpin RNAs against EVI1 or ITGB4. A–D. Two myeloid leukemia (UCSD/AML1 and MOLM1) and two primary AML
(PT9 and PT11) cell lines were treated with 1610
26 M Ara-C and anti-ITGA6 or ITGB4 antibodies for four days, and the viable cells were counted at
each indicated time point. The percent cell viability in comparison with the number of untreated cells on each indicated day is shown. E. The UCSD/
AML1 cells expressing shRNA for firefly luciferase (shLuc), ITGB4 (shITGB4) or EVI1 (shEVI1) were treated with Ara-C on BSA or matrigel-coated plates
for three days. The viable cells were counted at each time point. The relative cell viability is expressed as a percentage of the viability of the untreated
cells. Each experiment was performed in triplicate, and the experiments were independently repeated at least three times. The results are given as the
mean 6 S.E. The statistical analysis was performed using the Student’s t-test (**p,0.05, vs. control).
doi:10.1371/journal.pone.0030706.g005
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cell lines
The UCSD/AML1, MOLM1, PT9 and PT11 cells were plated
onto tissue culture plates with BSA or matrigel-coated wells and
subsequently incubated with 10
23 to 10
27 M cytosine-arabinoside
(Ara-C) for 48 h. The number of viable cells was determined using
trypan blue exclusion.
Neutralizing Antibody
The neutralizing antibodies used included rat anti-ITGA6
(Santa Cruz) and mouse anti-ITGB2, ITGB3 and ITGB4
(Millipore).
PCR and PCR primers
Total cellular RNA was isolated using Trizol (Invitrogen), and
the cDNA was prepared using oligo(dT) primer and reverse
transcriptase (SuperScript; Invitrogen). The polymerase chain
reaction (PCR) was performed using Ex Taq (Takara-Bio) on a
GeneAmp 2400 machine (Applied Biosystems). The primers for
all integrin family members, EVI1 and b-actin were produced
based on methods used in previous studies [12], [31]. The
primers for N and VE-cadherin were produced based on the
Quantitative PCR Primer Database (http://lpgws.nci.nih.gov/
cgi-bin/PrimerViewer). The primers for the laminin family genes
were produced based on Primer Bank (http://pga.mgh.harvard.
edu/primerbank/).
Introduction of small hairpin RNAs for EVI1, ITGA6, ITGB1
and ITGB4 in UCSD/AML1 cells
The pSIREN-retroQ-ZsGreen plasmid (Takara-Bio) was used
to inhibit EVI1 expression, and expression of ZsGreen (green
fluorescent protein) was used as a marker. The following sequences
were cloned into the BamHI-EcoRI sites of the pSIREN-retroQ-
ZsGreen plasmid to create shRNAs against human EVI1 [32], 59-
GATCGCTCTAAGGCTGAACTAGCAGTTCAAGAGACT-
GCTAGTTCAGCCTTAGATTTTTTG-39; human ITGA6,
59-GATCTCCTTTCAGGTTCAGTAGTTATTTCAAGAGAA-
TAGTTACTGAATCTGAGAGGTTTTTG-39; human ITGB1,
59-GATCTGGAGGGTTGTTTCGGGTTTCATTCAAGAGA-
TGAAGTCCGAAGTAATCCTCCTTTTTG -39; and human
ITGB4, 59-GATCGCCAGCGACTACACTATTGGATCTCG-
AGATCCAATAGTGTAGTCGCTGGTTTTTG (MISSION
shRNA library, Sigma). We used the pSIREN-retroQ-ZsGreen-
shLuc plasmid containing an shRNA against firefly luciferase
(Takara-Bio) as a control. The retroviral particles were generated
using the p10A1 packaging vector (Takara-Bio) via the transient
transfection of 293T cells. The transfection was conducted using
Hilymax liposome transfection reagent (Dojin). For retroviral
transduction, 1610
6 cells were plated onto a 6-cm dish containing
5 ml retroviral supernatant containing 100 ng/ml of polybrene for
24 h. After two weeks, the ZsGreen-positive cells were sorted using a
JSAN cell sorter (Bay Bioscience). The reduction of EVI1 or ITGB4
expression was confirmed using RT-PCR.
Establishment of stable U937 cell lines expressing EVI1
The pGCDNsam-EVI1-IRES-EGFP construct was kindly
provided by Dr. A. Iwama (Chiba University, Chiba, Japan). To
produce recombinant retrovirus, the plasmid DNA was transfected
into 293GP cells along with the vesicular stomatitis virus G (VSV-
G) expression plasmid via CaPO4 precipitation. For retroviral
transduction, 1610
5 U937 cells were plated onto 96-well flat-
bottomed plates and infected for 24 h with either an EVI1
retroviral supernatant (pGCDNsam-EVI1-IRES-EGFP) or a
control retroviral supernatant (pGCDNsam-IRES-EGFP) contain-
ing 100 ng/ml of polybrene. After 7 days, the green fluorescent
protein (GFP)-positive U937 cells were sorted using a JSAN cell
sorter (Bay Bioscience, Kobe, Japan).
Laminin-332 (laminin-5) knockdown in MC3T3-E1 cells
The pSIREN-retroQ-ZsGreen plasmid (Takara-Bio) was used
to inhibit the expression of the a3 chain of laminin-332, and the
expression of ZsGreen (GFP) was used as a marker. The following
sequence was cloned into the BamHI-EcoRI sites of the plasmid
to create an shRNA against the a3 chain of murine laminin-332:
59-GATCTGAACTCCTTAAATGATTATGAATTCAAGAG-
ATTCATAATCATTTAAGGAGTCTTTTTTACGCGTG-39.
The target sequence for the knockdown was determined using the
BLOCK-iT RNAi Designer (http://www.invitrogen.com/rnai).
We used pSIREN-retroQ-ZsGreen-shLuc containing shRNA
against firefly luciferase (Takara-Bio) as a control. We transiently
introduced the laminin-332 or luciferase shRNA expression vector
into MC3T3-E1 cells using an Amaxa Nucleofector (Lonza) and
determined the expression levels of the a3 and g2 subunits of
laminin-332.
Cell proliferation and cell viability assays
A cell proliferation assay was performed using a Cell Counting
Kit-8 (Dojin) according to the manufacturer’s protocol. Briefly,
5610
3 cells/well were plated onto a 96-well culture plate and
incubated for 1–3 days. Approximately 10 ml of Cell Counting
Kit-8 reagent was added to the plate, and the absorbance at 450
and 620 nm was measured using an Immunomini NJ2300 plate
reader (Nunc). A cell viability assay was performed using the Cell
Counting Kit-8 reagent according to the manufacturer’s protocol.
For this assay, 5610
3 cells were plated onto a 96-well culture plate
containing Ara-C (1610
26 M), rat anti-ITGA6 (20 mg/ml) or
mouse anti-ITGB4 (20 mg/ml). The cells were incubated for 1–2
days and 10 ml of Cell Counting kit-8 reagent was added. The
absorbance at 450 and 620 nm was measured. The cell viability
was calculated by dividing the value obtained for the treatment
well by the average value obtained for the control wells. For cell
viability assay, cells were seeded in 5610
4 cells/ml to matrigel
coated culture plate. Cells were co-cultured with Ara-C
(1610
26 M) and anti-ITGA6 antibody (20 mg/ml) or anti-ITGB4
(20 mg/ml) or isotype control IgG (20 mg/ml). After incubation
for 1 to 4 days, living cell numbers were counted by trypan blue
exclusion. The cell viability was calculated by dividing the value
for the treatment well by the value for the control wells. Each
Figure 6. Decreased cell growth with increased cell population in G0-phase of EVI1
high AML cells cultured on the matrigel-coated
plates. A. The UCSD/AML1 cells were transfected with shEVI1 (AML1/shEVI1) or control shLuc vector (AML1/shLuc) to determine their cell growth
under normal culture conditions on BSA or matrigel-coated plates. B and C. The cell cycle of AML1/shLuc as a control (B) and AML1/shEVI1 (C) were
analyzed using BD FACSCalibur after double staining with BrdU-APC and 7-AAD. The percentage of viable cells in each cell cycle is indicated with
white (BSA-coated) and black (matrigel-coated) bars. D. The percentage of AML1/shEVI1 (black bars) and AML1/shLuc (white bars) cells in the G0
phase cultured on matrigel or BSA-coated plates were analyzed using BD FACSCalibur after double staining with Ki67-Alexa647 and 7-AAD. Each
experiment was performed in triplicate, and the experiments were independently repeated at least three times. The results are shown as the mean 6
S.E. The statistical analysis was performed using the Student’s t-test (**p,0.01; **p,0.05, vs. control).
doi:10.1371/journal.pone.0030706.g006
Drug Resistance in EVI1+ AML with Integrin a6
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30706experiment was performed in triplicate. Data are shown as mean
6 S.E. Statistical analysis was performed using Student’s t-test.
Cell adhesion assay
Four types of extracellular matrices (ECM; matrigel, fibronec-
tin, laminin, collagen) and BSA (as a control) were used for the cell
adhesion assay. A culture plate was coated overnight with a 1/40
dilution of Growth Factor Reduced-Matrigel (BD Falcon), 5 mg/
cm
2 of fibronectin (BD Falcon), 5 mg/cm
2 of laminin (BD Falcon),
0.3 mg/ml of collagen (Nitta Gelatin) or 5% w/v BSA (Nacalai
Tesque). After coating with ECM, 1610
5 cells/ml were trans-
ferred to each pre-coated well and incubated for 24 h at 37uC.
After washing two times with phosphate buffered saline (PBS), the
floating and adherent cells were counted using trypan blue, and
the number of adherent cells was divided by the number of
floating cells to calculate the cell adherence ratios. In the
neutralization experiments, the cells were pre-incubated with
20 mg/ml of anti-ITGA6, ITGB2, ITGB3 or ITGB4 antibodies
prior to plating on the matrigel [33].
FACS analysis
The intensity of ITGB3, ITGB4 and ITGA6 expression in
UCSD/AML1 and U937 cells was analyzed using FACSCalibur
(BD Bioscience). The cells were stained with phycoerythrin (PE)-
labeled anti-human ITGA6 (Clone: GoH3), ITGB4 (Clone:
58XB4) or ITGB3 (BI-PL2) antibodies purchased from Biolegend,
Inc.
BrdU (Bromodeoxyuridine)/7-AAD (7-Aminoactinomycin
D) staining
To assess the percentage of cells in sub G0/G1, G0/G1, and
G2/M and S phase after 48 h of culture on matrigel or BSA-
coated plates, 1610
6 cells from each culture were fixed in BD
Cytofix/Cytoperm buffer for 20 min., followed by a 300-mg/ml
DNase treatment for 30 min. The cells were subsequently washed
twice in BD Perm/Wash Buffer and stained with anti BrdU-APC
(BD Biosciences/PharMingen, San Jose, CA) for 15 minutes,
followed by staining with 7-AAD (BD Biosciences/PharMingen,
San Jose, CA). The cells were harvested and analyzed using
FACSCalibur with FL-4 (for BrdU-APC) and FL-3 (for 7-AAD)
settings.
Ki67/7AAD staining
To assess the percentage of cells in G0 phase after 48 h of
culture on matrigel or BSA-coated plates, 1610
6 cells from each
culture were fixed in 70% ethanol for 2 h, followed by a 2.5 mg/ml
RNAse treatment for 30 minutes. The cells were subsequently
washed twice in PBS/1% fetal bovine serum (FBS) and stained
with mouse anti-human Ki67 (BD Biosciences/PharMingen, San
Jose, CA) and Alexa647-conjugated anti-mouse IgG (Invitrogen)
for 30 minutes, followed by staining with 7-AAD (BD Biosciences/
PharMingen, San Jose, CA). The cells were harvested and
analyzed using FACSCalibur with FL-4 (for Ki67-Alexa647) and
FL-3 (for 7-AAD) settings.
Statistical analysis
Student’s t-test was used to compare differences between the
two groups.
Supporting Information
Figure S1 Expression of integrin genes and cell binding
ability of various myeloid leukemia cells. A. The
expression of 25 members of the integrin family was detected
using semi-quantitative RT-PCR in HL60, U937, and K562 (cell
lines with EVI1
low expression) and in UCSD/AML1, MOLM1,
and HNT34 (cell lines with EVI1
high expression). The expression
of EVI1 and b-actin in these cells is also shown. B. The expression
of 18 genes in the integrin family was detected using RT-PCR in
AML1/shLuc and AML1/shEVI1 cell lines. C and D. The
adhesion ability of various HNT-34 cell lines (Pt, parental;/shLuc,
transfection with small hairpin RNA for firefly luciferase;/shEVI1,
transfection with small hairpin RNA for EVI1) to bind to matrigel
is shown in C, and the expression of integrin genes in conjunction
with EVI1 and b-actin is shown in D. E and F. The ability of
PT9-related (PT9/shLuc and PT9/shEVI1) and PT11-related
(PT11/shLuc and PT11/shEVI1) cell lines to bind to matrigel was
measured (E), and the expression of various integrin genes in these
four cell lines was determined using RT-PCR (F) G. The
expression patterns of integrin genes were determined in U937/
GFP and U937/EVI1 cell lines in conjunction with b-actin and
EVI1.
(DOC)
Figure S2 Expression of various laminin chains in
MC3T3-E1 cells. The relative expression levels of laminin a
chains 1 to 5, laminin b chains 1 to 3, and laminin g chains 1 to 3
in MC3T3-E1 cells were determined using semi-quantitative RT-
PCR.
(DOC)
Figure S3 Dose-response functions for AraC against
four EVI1high AML cells. UCSD/AML1, MOLM1, PT9 and
PT11 cells were incubated in BSA- or matrigel-coated wells of
tissue culture plates and subsequently incubated with 10-3 to 10-
7 M cytosine-arabinoside (Ara-C) for 48 h. Relative cell viability is
calculated as a percentage relative to standard controls. Data are
shown as mean 6 S.E. Statistical analysis was performed using
Student’s t-test. A star (*) indicates p,0.05 and double stars (**)
indicate p,0.01.
(DOC)
Figure S4 Drug sensitivity of EVI1
high and EVI1
low
leukemia cells cultured with or without MC3T3-E1 cells
determined by treatment with VP-16 or Ara-C. UCSD/
AML1 (EVI1
high) leukemia cells and HL60 (EVI1
low) leukemia
cells were treated with Ara-C or VP-16 for three days under plastic
flasks (open diamonds) or co-cultured with MC3T3-E1 cells
(closed squares); the viable cells were counted at each indicated
time point. The percent cell viability compared to the number of
untreated cells is shown for each indicated day. A star (*) indicates
p,0.05.
(DOC)
Figure S5 Decreased cell growth with increased cell
population in G0-phase of U937 cells with EVI1 expres-
sion cultured on the matrigel-coated plates. A. U937 cells
were introduced by EVI1 expression vector (U937/EVI1) or
control vector (U937/GFP) to determine their cell growths with
culture condition on BSA or matrigel-coated plates. B and C. Cell
cycle of U937/GFP as a control (B) and U937/EVI1 (C) were
analyzed by BD FACSCalibur after double-stained by BrdU-APC
and 7-AAD. Percentages of each cell cycles were shown by white
bars (BSA-coated) and black bars (matrigel-coated). D. The
percentage of cells in G0 phase in U937/EVI1 (black bars) and
U937/GFP cells (white bars) cultured on matrigel- or BSA-coated
plates were analyzed by BD FACSCalibur after double-stained by
Ki67-Alexa647 and 7-AAD. Each experiment was performed in
triplicate, and experiments were independently repeated at least
Drug Resistance in EVI1+ AML with Integrin a6
PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e30706three times. Results are shown as mean 6 S.E. Statistical analysis
was performed using Student’s t-test (**p,0.01; **p,0.05, vs
control).
(DOC)
Figure S6 Expression profiles of ITGA6 and ITGB4 in
AML patients. A and B. The expression patterns of ITGA6 (A)
and ITGB4 (B) are shown as gene expression profiles for ten AML
patients with EVI1low and ten AML patients with EVI1high
expression (http://www.ncbi.nlm.nih.gov/geo, accession number
GSE6891 [NCBI GEO]). C and D. The expression patterns of
ITGA6 (C) and ITGB4 (D) are shown as gene expression profiles
for patients in remission and for AML patients who had relapsed
(http://www.ncbi.nlm.nih.gov/geo, accession number GDS1059
[NCBI GEO]).
(DOC)
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